Immune-Mediated Liver Disease in the Transplanted Liver
Détails
ID Serval
serval:BIB_348144585B4E
Type
Partie de livre
Sous-type
Chapitre: chapitre ou section
Collection
Publications
Institution
Titre
Immune-Mediated Liver Disease in the Transplanted Liver
Titre du livre
Liver Immunology
Editeur
Springer International Publishing
ISBN
9783030517083
9783030517090
9783030517090
Statut éditorial
Publié
Date de publication
2020
Peer-reviewed
Oui
Numéro de chapitre
36
Pages
597-620
Edition
3e édition
Langue
anglais
Résumé
Liver transplantation has evolved as the treatment of choice for many patients with end-stage liver disease. Currently, survival posttransplant is excellent, with 10-year survival exceeding 65%. Causes of graft failure include recurrent disease, in particular autoimmune disease, alcoholic liver disease, and NAFLD. Immune-mediated injury is also a cause for graft failure, but this cause has proved to be less common nowadays. With the actual range of potent immunosuppressive agents and a greater use of a tailored approach, rejection is seen less frequently. Rejection may take the form of T-cell-mediated rejection (TCMR), antibody-mediated rejection (AMR), and plasma cell-rich hepatitis. On the opposite end of the spectrum, operational tolerance develops in a small proportion of liver transplant recipients. Finally, as indicated earlier, some autoimmune diseases can recur in the allograft.
Création de la notice
27/12/2021 11:49
Dernière modification de la notice
28/12/2021 6:37